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Background: The major surface glycoprotein (Msg) of Pneumocystis is encoded by approximately 50 to 80 unique
but related genes. Msg diversity may represent a mechanism for immune escape from host T cell responses. We
examined splenic T cell proliferative and cytokine as well as serum antibody responses to recombinant and native
Pneumocystis antigens in immunized or Pneumocystis-infected mice. In addition, immune responses were examined
in 5 healthy humans.
Results: Proliferative responses to each of two recombinant Msg variant proteins were seen in mice immunized
with either recombinant protein, but no proliferation to these antigens was seen in mice immunized with crude
Pneumocystis antigens or in mice that had cleared infection, although the latter animals demonstrated proliferative
responses to crude Pneumocystis antigens and native Msg. IL-17 and MCP-3 were produced in previously infected
animals in response to the same antigens, but not to recombinant antigens. Antibody responses to the
recombinant P. murina Msg variant proteins were seen in all groups of animals, demonstrating that all groups were
exposed to and mounted immune responses to Msg. No human PBMC samples proliferated following stimulation
with P. jirovecii Msg, while antibody responses were detected in sera from 4 of 5 samples.
Conclusions: Cross-reactive antibody responses to Msg variants are common, while cross-reactive T cell responses
are uncommon; these results support the hypothesis that Pneumocystis utilizes switching of Msg variant expression
to avoid host T cell responses.
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Pneumocystis is a fungus that can cause severe pneumo-
nia in immunosuppressed hosts, especially those with
HIV infection, but that can also cause pulmonary infec-
tion that is cleared by a robust immune response in
healthy hosts. While antibody responses are an import-
ant component of these responses, cell-mediated
responses appear critical to the successful control of
Pneumocystis infection [1,2]. Pneumocystis can infect a
wide range of host species, and each host is infected by
a genetically unique Pneumocystis species. Serologic
studies among humans suggest widespread exposure to
Pneumocystis at an early age [3].* Correspondence: jkovacs@mail.nih.gov
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reproduction in any medium, provided the orThe most abundant surface protein is an ~95,000-
110,000 MW protein known as the major surface glyco-
protein (Msg, also called gpA; Figure 1) [4]. Msg appears
to play a role in mediating adhesion to host cells, possibly
through binding to fibronectin or vitronectin [5,6]. Msg
is encoded by a family of approximately 50 to 80 genes
which are related but distinct; each Pneumocystis species
examined to date encodes a similar multi-copy gene fam-
ily [7,8]. While multiple different Msgs may be expressed
in a heavily infected immunosuppressed animal [9], a sin-
gle organism can express only a single Msg [10-13].
Pneumocystis has developed a mechanism whereby there
is a single expression site for msg genes [10-13]; the gene
to be expressed must be placed downstream of and in-
frame with the upstream conserved sequence (UCS),
which serves as a leader for Msg and encodes a signal
peptide for trafficking to the endoplasmic reticulum. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 SDS-PAGE analysis of native Msg. Msg was purified as
described in the methods and then analyzed by SDS-PAGE; the gel
was stained with Coomassie Blue. Lane 2 shows Msg (arrow) with an
approximate size of ~95 kilodaltons. Molecular weight markers are in
lane 1, with their size in kilodaltons indicated on the left.
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but may involve gene conversion.
While Msg may play a functional role in Pneumocystis
biology such as in facilitating adhesion, the presence ofmultiple Msg variants strongly suggests that Pneumocys-
tis has developed a mechanism for antigenic variation,
similar to other organisms such as trypanosomes or Bor-
relia [8,14]. Antigenic variation could potentially allow
persistence of infection or facilitate re-infection, contrib-
uting to the ubiquitous nature of this organism. Although
Pneumocystis is a pathogen of immunosuppressed hosts,
Pneumocystis can infect and induce a brisk and effective
immune response in immunocompetent hosts [15,16].
Antigenic variation presumably evolved to evade host
responses in the latter, given that immunosuppressed
hosts would likely rarely be encountered in nature.
Antigenic variation in many pathogens is designed to
avoid humoral immune responses [14]. In Pneumocystis,
although antibodies play a role in protection, cellular im-
mune responses, especially CD4+ T cell responses, are
critical for clearing infection and providing protective
immunity [1,2]. We hypothesized that a primary benefit
of maintaining a broad Msg repertoire is to allow
switching of the expressed Msg variant to evade cellular
immune responses, especially CD4+ T cell responses,
given that Pneumocystis is exclusively an extracellular
pathogen. The current study was undertaken to address
this hypothesis by examining: 1. cellular and humoral
responses in mice to two recombinant Msg variants fol-
lowing immunization with recombinant proteins or na-
tive Pneumocystis antigens, as well as following natural
infection; and 2. cellular proliferative and humoral
responses in humans to a recombinant Msg variant.
Results
In order to study immune responses in mice to individ-
ual Msgs, we expressed 2 recombinant Msg variants,
107 and 119, which differed from each other by 11%, in
E. coli. Because of difficulties in expressing the entire
Msg as a single protein, we expressed each variant in
two overlapping fragments, corresponding approxi-
mately to the amino and carboxyl halves of the full-
length protein. In addition, we expressed each fragment
in multiple vectors, one of which was used for
immunization studies, and another for in vitro assays.
This eliminated cross-reactive immune responses to the
vector-encoded portion of the recombinant protein
which we identified in preliminary studies.
We utilized proliferation to examine cellular T cell
responses to Pneumocystis antigens; this will primarily
represent CD4+ T cell responses to protein (vs. peptide)
antigens. In a subset of animals we also examined cul-
ture supernatant cytokine levels following antigenic
stimulation. Attempts to detect intracellular cytokine
responses, including interferon-gamma, interleukin-4,
interleukin-17, and tumor necrosis factor-alpha, by flow
cytometry were unsuccessful despite numerous attempts
using a variety of Pneumocystis antigens.
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4 times with the amino fragment of each of the two re-
combinant Msg variants 107 and 119 (20 μg/
immunization), because there was less conservation in
the amino (86%) compared to the carboxyl (91%) frag-
ments. We examined proliferative and antibody
responses to both variants; results are shown in Figure 2.
Splenocytes from one of 4 mice immunized with a single
dose of Msg119Am proliferated in response only to the
immunizing antigen. No proliferation was seen to either
the immunizing or the non-immunizing variant frag-
ment following 2 immunizations with either amino frag-
ment. Following the 4th immunization, proliferative
responses to the immunizing antigen were seen in sple-
nocytes from 6 of 8 animals, while proliferation to the
non-immunizing Msg amino fragment was seen in sple-
nocytes from 5 of these 8 animals. In contrast, antibody
responses as measured by ELISA were seen in 5 of
the 8 animals to both fragments following the first
immunization, and in 16 of 16 animals to both frag-
ments following 2 or 4 immunizations; optical densities
were similar to both fragments regardless of whether
107 or 119 was used for immunization. Antibody
responses to crude P. murina antigens were seen only
in animals with antibody responses to the Msg variants
(20 of 24 animals). Thus, cross-reactive proliferative
responses were seen only following multiple immuniza-
tions, while cross-reactive antibody responses were seenFigure 2 A. Cell proliferation following immunization with recombina
Splenocytes from animals that were immunized with these recombinant M
Msg proteins and (as a control) with recombinant protein encoded by the
four injections with each antigen, as indicated by 1X, 2X, and 4X. Bars repre
stimulated response divided by empty vector-stimulated response). B. Anti
were run in duplicate for each antigen. Bars represent the mean optical de
used to compare the results for immunized animals to control (unimmuniz
the following symbols: *, p≤ 0.05; {, p≤ 0.01; †, p≤ 0.001.after a single immunization. No immune responses were
seen to the recombinant Msg fragments or crude P.
murina antigens in control animals immunized with ad-
juvant alone (data not shown).
To verify that the antibody responses to recombinant
proteins recognized native Msg, we utilized western
blots with either crude Pneumocystis antigens or purified
native Msg as the antigen. Using sera from animals
immunized with the amino recombinant fragments, we
were able to demonstrate reactivity with Msg in both
antigen preparations in 2 of 2 animals tested. Figure 3
shows results using sera from animals immunized with
107Am or 119Am.
We next examined proliferative and antibody re-
sponses following immunization with crude P. murina
antigens. Msg is the most abundant protein in Pneumo-
cystis extracts, and in immunosuppressed animals, which
are the source of this Pneumocystis, multiple Msg var-
iants are expressed [9]. Splenocytes from immunized
animals (n = 5) did not proliferate in response to chal-
lenge with either the amino or the carboxyl fragment of
either MSG107 or MSG119, but did proliferate (5 of 5
animals) to crude P. murina antigens, which were used
to immunize the animals (Figure 4). Proliferative
responses were also seen to purified native Msg in sple-
nocytes from immunized animals (2 of 2) but not in a
control animal. In contrast to this, antibody responses
were seen to both amino (4 of 5 for 107Am and 3 of 3nt P. murina Msg proteins MSG107Am and MSG119Am.
sg proteins were cultured in triplicate with each of the recombinant
empty vector (without Msg). Groups of 4 animals received one, two or
sent the stimulation index (SI) (geometric mean of results for Msg-
body reactivity to the Msg variants measured by ELISA. Serum samples
nsity for 4 animals per immunization group. Unpaired t tests were
ed or adjuvant alone) animals. Statistical significance is indicated by
Figure 3 Western blot analysis of antibody responses generated following immunization with recombinant Msg. Panel A shows a
Coomassie blue-stained gel and panel B shows western blots using sera from 2 immunized mice and 1 control mouse. For both the gel and the
blots, lane 1 utilized a crude Pneumocystis antigen extract, while lane 2 utilized purified Msg. For the western blots, the serum used to probe the
blots is shown under the blot. 107Am is from an animal that received 4 immunizations with MSG107Am, and 119Am is from an animal that
received 4 immunizations with MSG119Am. No Ag is from an animal immunized with adjuvant alone. Brackets indicate the location of Msg. The
Msg in purified preparations is smaller than in crude preparations because lyticase treatment, which is used to solubilize Msg, results in a
decrease in the apparent molecular weight of Msg.
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MSG119, as well as to crude P. murina antigens, in all 5
animals. Antibody responses were also seen to purified
native Msg (2 of 2). It is noteworthy that the antibody
responses were greater (higher OD) to both carboxyl
fragments, which are more highly conserved, than to the
amino fragments. The antibody responses demonstrate
that the animals were exposed to, and were able to
mount an immune response to, Msg in the crude anti-
gen preparations.
Because immunization with either recombinant or
crude antigen preparations presents an artificial encoun-
ter with Pneumocystis antigens, we wanted to examine
immune responses following natural infection. Since im-
munosuppressed animals have inadequate immune
responses to Pneumocystis, which allow the organism to
replicate in an uncontrolled or poorly controlled man-
ner, we utilized a model in which healthy animals de-
velop Pneumocystis infection following exposure to an
already infected seeder animal. In this model, infection
peaks at ~5-6 weeks following exposure, and is typically
cleared by 10 weeks [15]. Splenocytes from exposed
mice proliferated in response to crude Pneumocystis
antigens in 7 of 9 animals and to native Msg in 2 of 2
animals, but none of the animals showed proliferation to
any of the 4 recombinant Msg protein fragments(Figure 5). Antibody responses were again seen to the
carboxyl recombinant Msg fragments (9 of 9 and 8 of 9
for MSG107 and MSG119, respectively) as well as to
crude Pneumocystis antigen and native Msg (8 of 9 for
each), but not to the amino fragments (0 of 9 and 1 of 7
for MSG107 and MSG119, respectively), again indicating
that these naturally infected animals were exposed to
Msg.
As an additional marker of CD4 responses, we exam-
ined in vitro cytokine production. Among the cytokines
examined, IL-17 and MCP-3 were consistently secreted
by splenocytes from animals infected with P. murina
when cultured with P. murina Ag or native Msg antigen,
but not with the recombinant Msg variants (Figure 6).
These responses represented memory responses, as no
cytokine production was seen in cells from uninfected
control animals cultured with the same antigens. Among
the other cytokines, results with crude antigen or native
Msg were variably positive (data not shown) but in no
case were they produced in response to the recombinant
antigens.
Serologic studies have found that most humans have
been exposed to Pneumocystis at a young age and have
detectable antibodies to Msg. To see if PBMCs from
healthy humans can proliferate to recombinant Msg, cells
from 5 volunteers were cultured with HuMSG14Am,
Figure 4 A. Cell proliferation following immunization with crude Pneumocystis antigens. Splenocytes from animals that were immunized
four to five times with crude antigens were cultured in triplicate with recombinant P. murina Msg proteins (n = 5 except n = 3 for MSG119Am),
crude Pneumocystis antigens (n = 5), and purified native Msg (n = 2). Non-immune animals or animals immunized with normal lung antigen were
used as controls and splenocytes were cultured with the same antigens (n = 4 for all except n = 3 for MSG119Am and n= 1 for purified native
Msg). Bars represent the stimulation index (SI) as compared to appropriate vector without Msg for recombinant antigens, normal lung antigens
for crude Pneumocystis antigens and no antigen for native Msg. B. Antibody reactivity to each of the antigens measured by ELISA. Serum samples
were run in duplicate for each antigen. Each bar in B represents the mean optical density for each antigen in Pneumocystis antigen immunized or
control immunized animals (the same number of animals were used as for A). Unpaired t tests were used to compare the results for immunized
animals to control (normal lung immunized) animals. Statistical significance is indicated by the following symbols: *, p≤ 0.05; {, p≤ 0.01; †,
p≤ 0.001. For native Msg statistical significance was not calculated due to the small number of animals.
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tient demonstrated proliferation to either HuMSG frag-
ment after 5 days, while all samples proliferated in
response to concanavalin A or tetanus toxoid. More-
over, sera from 4 of the 5 volunteers were positive in an
ELISA utilizing HuMSG14Ca, while the 5th volunteer
had high non-specific reactivity.
Discussion
This study has demonstrated that while cross-reactive
proliferative responses to two distinct recombinant Msg
variants were induced by multiple immunizations with
recombinant Msg protein, proliferative responses to
these recombinant proteins were not seen following
immunization with crude Pneumocystis antigens, which
contain Msg, or following natural infection in a healthy
host. Further more, these proteins did not induce IL-17
and MCP-3 production in infected animals, unlike the
crude antigen or purified native Msg. In contrast, nearly
all animals developed antibody responses to the recom-
binant Msg fragments, indicating that they recognized
conserved B cell epitopes in Msg. Since the cell-
mediated (proliferation and cytokine) responses to extra-
cellular proteins represent primarily CD4+ T cell
responses, these data are thus consistent with the hy-
pothesis that Msg variants exhibit antigenic variation
that evades CD4-mediated T cell responses rather than
B cell responses. Because in vitro culture and geneticmanipulation of Pneumocystis is not currently possible,
more direct methods for addressing this question, such
as utilization of organisms that express a single msg
gene, are currently not feasible, and thus indirect meth-
ods, as in the present study, must be utilized.
CD4 cells are critical to controlling infection with
Pneumocystis, and CD4 responses have previously been
shown to target Msg. Further, immunization with Msg
has been shown to induce proliferative responses [17]
but such immunization did not provide complete pro-
tection against Pneumocystis infection [17,18].
Western blot studies demonstrated that the antibodies
generated following immunization with recombinant
proteins recognized native Msg that was purified or
present in crude antigen extracts. Thus conformational
differences or differences in post-translational modifica-
tions that may exist between native and recombinant
proteins did not prevent development of cross-reactive
antibodies. While T cell responses were not detected,
this cannot be due to conformational differences since
both CD4 and CD8 cells recognize processed peptides
of ~8-10 amino acids that are not dependent on
conformation.
We initially examined immune responses following
immunization with recombinant Msg variants, and
found cross-reactivity in both proliferation and anti-
body responses after 4 immunizations, but only anti-
body responses following a lower exposure (1 or 2
Figure 5 A. Cell proliferation following Pneumocystis infection. Blood and spleen cells were obtained 10 to 12 weeks after initial exposure to
Pneumocystis-infected seeders, a time by which Pneumocystis infection has typically developed and been cleared in healthy, immunocompetent
animals. Splenocytes from these animals were cultured with recombinant P. murina Msg proteins (n = 9 except n = 7 for MSG119Am), crude
Pneumocystis antigens (n = 9), and purified native Msg (n = 2). Splenocytes from unexposed control animals were cultured with the same antigens
(n = 4 for all except n = 3 for MSG119Am and n= 1 for native Msg). Bars represent the stimulation index (SI) as compared to proliferation to
appropriate vector without Msg for recombinant antigens and normal lung antigens for crude Pneumocystis antigens and no antigen for native
Msg. B. Antibody reactivity to each of the antigens measured by ELISA. Each bar represents the mean optical density of the Pneumocystis
exposed or control animals (the same number of animals were used as for A). Of note, 1 of 7 Pneumocystis exposed animals had antibodies to
MSG119Am. Unpaired t tests were used to compare the results for exposed animals to control (unexposed) animals. Statistical significance is
indicated by the following symbols: *, p≤ 0.05; {, p≤ 0.01; †, p≤ 0.001. For native Msg (left panel) statistical significance was not calculated due
to the small number of animals.
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that we could detect in vitro proliferation to the re-
combinant Msg proteins. Of note, the animal that
showed proliferation after only 1 immunization prolif-
erated only to the immunizing Msg variant, but devel-
oped antibodies that reacted with both Msg variants.
No animals showed proliferative responses in the ab-
sence of antibody responses. These data suggest that
CD4 responses, as measured by proliferation, require
repeat or prolonged exposure to Msg. Such repeated
exposure may allow for the expansion of a small num-
ber of initially responsive T cells or recruitment of
new T cells recognizing additional Msg epitopes.
Interestingly, animals immunized with crude P. murina
antigens demonstrated proliferative responses to the im-
munizing antigen and to purified native Msg, but not to
either of the recombinant Msg variants, including the
more conserved carboxyl portions (MSG107Ca and
MSG119Ca). A likely explanation for this observation is
that the genes encoding MSG107 and MSG119 were not
expressed by the P. murina organisms used for prepar-
ation of the crude antigen, since only 1 of the 50 to 80
Msg genes is expressed by a P. murina organism at a time
[10-13]. While some of these cellular responses may also
be to other P. murina antigens, possibly Kexin or other
unidentified P. murina antigens [19-23], proliferation fol-
lowing exposure to native Msg clearly demonstrates thatcellular responses were directed in part against Msg.
Although the number of animals studied using native Msg
was small, precluding statistical analysis, the results were
consistent with and supportive of those using crude
antigen.
Finally, naturally infected animals showed production
of IL-17 and MCP-3 and proliferation to crude P. mur-
ina antigen and to native Msg protein but again lacked
cross-reactive proliferative responses to either the amino
or carboxyl portions of Msg variants. Antibody re-
sponses were seen to the more conserved carboxyl frag-
ment in most animals. Because we are not able to
identify Msg variants that are expressed by Pneumocystis
in individual naturally infected immunocompetent ani-
mals, we could not directly examine proliferative
responses to the Msg variants that were expressed by
the infecting organism, nor could we compare their
sequences to those of the recombinant Msgs that were
utilized in the in vitro assays.
Our results are in contrast to those of Theus et al. [24]
who demonstrated proliferative responses to a recom-
binant Msg protein as well as to native Msg, using sple-
nocytes and T cell clones from naturally infected rats. It
is possible that the recombinant protein used in those
studies was identical to or more closely related to the
Msg variants expressed by Pneumocystis during infection
of those animals. Interestingly, immunization with native
Figure 6 Analysis of cytokines secreted by splenocytes from Pneumocystis-infected animals. Splenocytes were obtained 10 to 12 weeks
after exposure, by which time Pneumocystis infection had typically cleared, and were cultured with recombinant Msg proteins, crude Pneumocystis
antigens, or native Msg. A shows the results for IL-17, and B, the results for MCP3. Results for IL-17, top, represent the average of 7 P. murina
exposed animals or 3 unexposed control animals (except for concanavalin A, n = 2) and bottom, the average of 2 P. murina exposed animals or
results for 1 unexposed control animal. Results for MCP-3, top, represent the average of 4 P. murina exposed animals (except n = 3 for crude P.
murina antigen) or 2 unexposed control animals and bottom, the average of 2 P. murina exposed animals (except concanavalin A, n = 1) or
results for 1 unexposed control animal. The dashed line in each panel indicates the lower limit of detection; the error bars indicate the standard
deviation. Unpaired t tests were used to compare the results for exposed animals to control (unexposed) animals. Statistical significance is
indicated by the following symbols: *, p≤ 0.05; {, p≤ 0.01; †, p≤ 0.001. Statistical significance was not calculated for the bottom panels due to
the small number of animals. Although the results for MCP-3 (top panel) did not reach statistical significance (p = 0.054), all 3 animals had
elevated MCP-3 levels in response to crude Pneumocystis antigen, and both animals in the bottom panel showed elevated levels to both crude
Pneumocystis antigen and native Msg. In the top panels, error bars are not shown for the results that are below the lower limit of detection, since
results for all animals in each group were below that value. In the bottom panels, error bars are not shown for the single unexposed animal.
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from Pneumocystis pneumonia, leading to a lower organ-
ism burden, while immunization with native Msg in
mice was not protective, though antibody responses
were induced in both studies [17,18].
We attempted to detect antigen-specific responses by
intracellular cytokine staining using Pneumocystis anti-
gens that were positive in the proliferation assays, but
were unable to detect such responses despite utilization
of a variety of assay conditions. We are aware of no pub-
lication to date that has successfully identified Pneumo-
cystis-specific responses using this assay. This may be in
part a function of the host-specific response toPneumocystis, since such responses have been easily
identified for many other pathogens [25].
Serologic studies have demonstrated that most
humans are exposed to Pneumocystis at an early age [3];
consistent with this, most humans, including those
included in the current study, have antibodies to Msg.
While we were not able to perform the same spectrum
of studies in humans as in mice, we were able to demon-
strate, in previously infected humans (based on ser-
ology), absence of proliferative responses to a
recombinant Msg to which they maintained antibody
responses. Although the total number of patients studied
is small, and while it’s possible that the proliferative T
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with the animal data these results support the concept
that antigenic variation helps avoid T cell, but not B cell,
mediated immune responses. Very few studies have
examined immune responses to Pneumocystis-specific
antigens in humans, and all published studies have uti-
lized rodent-derived antigens, which raises concerns that
detected responses are non-specific, targeting xenogen-
eic, host-derived antigens, rather than being Pneumocys-
tis-specific [26-28]. Additional studies such as ours, that
utilize purified or recombinant P. jirovecii-derived anti-
gens, are clearly needed to better understand the inter-
action between Pneumocystis and humans.Conclusions
This study has shown that in mice, cellular responses
(proliferation and cytokine production) and antibody
responses to variants of the Msg of Pneumocystis are dis-
cordant. Cross-reactive antibody responses occur follow-
ing immunization with recombinant or native antigens,
as well as following natural exposure to Pneumocystis,
while cross-reactive cellular responses are not seen fol-
lowing immunization with native antigens or following
natural exposure. The Pneumocystis genome contains
multiple msg gene variants, only one of which is
expressed in an organism, which thus confers upon
Pneumocystis the potential for antigenic variation to
avoid host immune responses. Given that cross-reactive
cellular responses were not seen following immunization
with native antigens or following natural exposure, while
cross-reactive antibody responses were seen in these
same animals (demonstrating response of their immune
system to Msg), our results support the concept that
antigenic variation in Pneumocystis has evolved to evade
cellular rather than antibody responses. This is consist-
ent with the observation that Pneumocystis pneumonia
occurs almost exclusively in hosts with predominantly
cellular immunodeficiencies, such as HIV infection,
reflecting the importance of cellular immune mechan-
isms in control of this infection.Methods
Animals
Healthy Balb/c, Balb/c scid, and C57 black (C57BL) mice
were obtained from the National Cancer Institute, and
CD40 ligand knock-out (CD40L-KO, strain B6, 129 S-
Tnfsf5tm1lmx) mice were obtained from Jackson Labora-
tory. BALB/c scid and CD40L-KO mice were subse-
quently bred at the NIH. Mice were housed in
microisolator cages and kept in ventilated racks. All ani-
mal work was performed under an NIH Clinical Center
Animal Care and Use Committee-approved protocol.Human samples
Serum and peripheral blood mononuclear cells (PBMCs)
were obtained from anonymous healthy NIH blood bank
volunteers under IRB approved protocols. Guidelines of
the National Institutes of Health and the US Department
of Health and Human Services were followed in the con-
duct of these studies.
P. murina antigen preparation
Crude antigens for immunization and cell proliferation
assays were prepared from scid lungs heavily infected
with P. murina (as determined by Diff Quik staining) or
from uninfected wild-type lungs by homogenization in
PBS (0.25 g/mL) using a Polytron (Omni International)
followed by sonication. The homogenate was centrifuged
for 10 minutes at 20,000 g, and the supernatant was col-
lected. Pneumocystis antigens for ELISA were prepared
in a similar manner from Pneumocystis organisms that
were partially purified by Ficoll-Paque (GE Healthcare)
gradient centrifugation. Glycerol was added to a final
volume of 10% and the preparations were filter sterilized.
Protein concentrations were determined using BCA
(Pierce Biotechnologies).
Native Msg was prepared from partially purified P.
murina organisms that were treated with lyticase
(Sigma-Aldrich) overnight at 37°C [4]. Following centri-
fugation, Msg was purified from the supernatant using a
concanavalin A-based glycoprotein isolation kit (Thermo
Scientific). The buffers were changed to PBS plus 10%
glycerol using a Microcon centrifugal filter device (Milli-
pore). The protein concentration was determined by
BCA or by measuring the absorbance at 280 nm using a
NanoDrop spectrophotometer (Thermo Scientific) and
purity was determined by SDS-PAGE (Figure 1).
Recombinant Msg antigen preparation
DNA extracted from P. murina–infected scid mouse
lung tissue was used as a template to amplify major sur-
face glycoprotein (msg) genes of P. murina (which do
not contain introns) by PCR. To facilitate expression,
the region encoding a hydrophobic tail was excluded
from the amplicon. PCR products were cloned into the
pCR2.1 TA cloning vector (Invitrogen). msg clones were
sequenced and two gene variants with among the high-
est differences (89% identity) at the amino acid level
were chosen for protein expression: MSG107 (Accession
# JF308632) and MSG119 (Accession # JF308633). Be-
cause of difficulty in expression of full-length Msg pro-
teins, each msg was cloned into 2 fragments, MSG-Am
and MSG-Ca, which encode the amino portions and
carboxyl portions of the Msg proteins, respectively.
MSG107Am and MSG119Am were 86% identical at the
amino acid level and MSG107Ca and MSG119Ca were
91% identical at the amino acid level. Each of the MSG-
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vectors pET32a (Novagen), pGEX-6P-1 (GE Healthcare,
Life Sciences) and pMALc2X (New England Biolabs),
modified with the addition of a histidine tag and kindly
provided by Dr. Peter Burbelo. MSG-Am proteins were
expressed in BL21-CodonPlus (DE3)-RIL cells (Strata-
gene) and then purified using a Ni-NTA agarose (Qia-
gen) column or GST Purification module (GE
Healthcare, Life Sciences) [29]. Because of difficulty in
expression in bacterial systems, the MSG-Ca proteins
were cloned into a modified pCEPPu/BM40 eukaryotic
expression vector [30], kindly provided by Dr. Craig
Rhodes, expressed in Cos1 cells and purified using Ni-
NTA agarose (Qiagen). The buffers were changed to
PBS, 10% glycerol and the proteins were concentrated
using Amicon Ultra or Centricon centrifugal filter
devices (Millipore). Endotoxin was removed from pro-
teins expressed in E. coli systems using Triton X-114
[31]; endotoxin levels in the final preparations were
below 0.05 EU/ml as measured by QCL-1000 Endpoint
Chromogenic LAL Assay (Lonza). Recombinant Msg
protein concentrations were determined using BCA.
HuMSG14 (GenBank accession no. AF033209) [32] a
P. jirovecii msg gene, was cloned in 2 fragments, HuMS-
G14Am (encoding the amino portion) and Hu-
MSG14Ca (encoding the carboxyl portion) into pET32a,
and expressed in BL21-CodonPlus (DE3)-RIL cells (Stra-
tagene). Recombinant Msg proteins were purified using
a Ni-NTA agarose (Qiagen) column as previously
described [33].
Immunizations
Healthy Balb/c or C57BL mice were immunized sub-
cutaneously with approximately 475 μg crude P. murina
or normal lung antigen, or 20 μg recombinant Msg anti-
gen using Freund’s complete adjuvant, and boosted with
one to four additional injections using Freund’s incom-
plete adjuvant. Approximately 2 weeks following the last
injection, mice were sacrificed and their spleens and
blood were collected.
P. murina exposure
To replicate natural infection, healthy C57BL mice were
co-housed with a P. murina-infected (scid or CD40L-KO)
seeder mouse or in control cages without a seeder mouse.
After 10 to 12 weeks of exposure, by which time
healthy, immunocompetent mice have typically cleared
Pneumocystis infection and have detectable immune
responses [15,16], mice were sacrificed and their spleens
and blood were collected.
Cell proliferation assay
Mouse spleen cells were cultured in 96 well plates
(100,000 cells per well) with concanavalin A (2.5 μg/ml)for 4 days, and P. murina antigen (100 μg/ml), normal
mouse lung antigen (100 μg/ml), recombinant Msg anti-
gens (5 μg/ml), recombinant vector antigen (recombin-
ant protein from the vector with no msg insert) (5 μg/
ml), native msg antigen (2.5 μg/ml) or no antigen for
5 days. Similarly, human PBMCs were cultured in 96
well plates (100,000 cells per well) with concanavalin A
(25 μg/ml) for 4 days or tetanus (1:10 dilution) for 5 days,
and with recombinant HuMSG14Am or HuMSG14Ca
(0.1 to 10 μg/ml) or no antigen for 5 days. To demon-
strate that native or recombinant Msg proteins are not
toxic to cells, in some experiments human PBMCs or
mouse splenocytes were cultured with concanavalin A
plus recombinant Msg antigens or native Msg. No inhib-
ition of proliferation was seen in these studies.
Cell proliferation was measured after 4 to 5 days of
culture using tritiated thymidine incorporation (triplicate
wells) or CellTiter-Glo Luminescent Cell Viability Assay
(duplicate or triplicate wells; Promega) [34]. For the
former, 0.4 μCi tritiated thymidine was added to each
well, cells were incubated at 37°C for an additional
4 hours, then harvested onto FilterMAT (Skatron Instru-
ments) using a Tomtec Mach II M cell harvester, and
counted using a scintillation counter (Beckman). CellTi-
ter Glo was used according to the manufacturer’s
instructions. Luminescence was read on a Centro LB
960 luminometer (Berthold Technologies). Results are
presented as stimulation index, which represents the
fold-change compared to the respective vector with no
insert for recombinant antigens, normal lung antigen for
crude Pneumocystis antigen, and no antigen for native
msg; a stimulation index of 3 or greater was considered
positive.
Cytokine secretion
Fresh mouse spleen cells were cultured in 24 or 96 well
plates at 0.5-1.0 X106 cells per ml with recombinant Msg
antigens, P. murina antigen, native Msg antigen, or con-
canavalin A at the same concentrations used in the cell
proliferation assays. Cells were incubated at 37°C for
72 hours and the supernatants were harvested and stored
at -80oC. Secreted cytokines were detected in the cell cul-
ture supernatants using Procarta Cytokine Assay Kits
(Affymetrix) using a Bio-Plex 200 instrument (Bio-Rad).
The following cytokines were assayed: IL-1 beta, IL-2, IL-
6, IL-10, IL12p70, IL-17, IL-23, interferon-gamma, GM-
CSF, TNF-alpha, MCP-3, and IP-10; IL-4, IL-15, IL-21,
and KC were assayed in a subset of samples.
Immunoblot
Approximately 34 μg crude P. murina antigen and
0.3 μg native msg antigen were run on a 4-20% Tris-
Glycine SDS-PAGE gel (Invitrogen). Proteins were
stained with Coomassie blue or were transferred onto a
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the membranes were incubated with mouse sera diluted
1:100 followed by peroxidase conjugated anti-mouse IgG
antibody (Jackson ImmunoResearch Laboratories). Re-
activity was detected using 3,3’,5,5’-Tetramethylbenzidine
(TMB) substrate (Sigma-Aldrich).
ELISA
Anti-P. murina serum antibodies were measured by
ELISA as previously described [15]. Briefly, native Msg
(0.5 μg/ml), recombinant Msg (2.5 to 5 μg/ml), or
Pneumocystis antigens prepared from partially purified
P. murina organisms (1.6 μg/ml) were bound to dupli-
cate wells in a 96 well plate at 37°C for 2 hours. After
washing, the wells were blocked with 5% milk plus 5%
goat serum in PBS at 37°C for 2 hours and then over-
night at 4°C. The wells were then incubated with 100 μl
mouse serum diluted 1:100 in 5% milk plus 5% goat
serum in PBS with 0.05% Tween 20 for 1 hour at room
temperature, and then after washing were incubated
with HRP-conjugated goat anti-mouse IgG (heavy + light
chains) (Jackson ImmunoLabs) diluted 1:1000 in 5%
milk plus 5% goat serum in PBS with 0.05% Tween 20
for 1 hour at room temperature. After washing, 100 μl
OPD substrate (Sigma) was added to each well. Optical
densities (450 nm) were read at 1 hour. Anti-P. jirovecii
Msg antibodies were measured by ELISA as previously
reported [33].
Statistical analysis
For analysis of the proliferation data, the results were
log2 transformed to normalize the data, and a two-
sample t-test assuming unequal variance was performed
using Excel (Microsoft). The geometric mean data were
back-transformed for presentation of the results. For
analysis of the ELISA and cytokine results, the same t-
test analysis was performed on untransformed data.
Values below the detection of the cytokine assays were
set at the detection limit for this analysis.
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